Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

Latest News

Indonesia imposes moratorium on new palm oil plantations

Sep 23, 2018

JAKARTA, Indonesia — Indonesia's president has signed a moratorium on new palm oil development and ordered a review of existing plantations, an official said Thursday, in a blow to an industry blamed for environmental destruction and worker exploitation. Prabianto Mukti Wibowo, a deputy minister at the Coordinating Ministry for Economic Affairs, said the moratorium, first announced by president Joko Widodo after devastating fires in 2015, will last three years. He told The Associated Press it's needed because many planned plantations are inside natural forests and also to clarify the legal rights of villagers and smallholders. Palm oil, mainly produced in...

Stocks up despite trade dispute, oil drops on Trump threat

Sep 23, 2018

SINGAPORE — European markets climbed Thursday following a mixed day in Asia, buoyed by hopes the U.S. and China will proceed with talks to tackle their escalating trade dispute. The price of oil dropped after U.S. President Donald Trump warned OPEC to ensure production increases, as they promised this summer. KEEPING SCORE: France's CAC 40 rose 0.8 percent to 5,440 and Germany's DAX gained 0.7 percent to 12,297. Britain's FTSE 100 rose 0.2 percent to 7,346. Wall Street was set for small gains on the open. Dow futures added 0.2 percent while the S&P 500 future rose 0.1 percent. ASIA'S...

Malaysia's ex-PM pleads not guilty to new corruption charges

Sep 23, 2018

KUALA LUMPUR, Malaysia — Former Malaysian Prime Minister Najib Razak pleaded not guilty Thursday to 25 new charges of abuse of power and money laundering over the multimillion-dollar looting of a state investment fund. This brings the number of charges against Najib to 32 since his shocking election defeat in May 9 national polls. Wearing a blue suit and tie, Najib was calm as he pleaded not guilty in a crowded courtroom to four counts of abusing his power to receive a total of 2.3 billion ringgit ($556 million) from 2011 to 2014. He will also stand trial on 21...

Asian shares track optimism on Wall Street over tariffs

Sep 23, 2018

SINGAPORE — Asian markets were mostly higher on Thursday with narrow trading after news of a fresh round of tariffs by the U.S. on $200 billion in Chinese goods received a muted reaction on Wall Street. KEEPING SCORE: Japan's Nikkei 225 was flat at 23,672.91, ahead of the ruling Liberal Democratic Party's leadership vote. Japanese Prime Minister Shinzo Abe is widely expected overcome a challenge and receive the go-ahead for his third three-year term. The Kospi in South Korea added 0.7 percent to 2,325.04. Hong Kong's Hang Seng index gained 0.4 percent to 27,528.36. The Shanghai Composite index was almost...

World stocks advance, unfazed by new US-China tariffs

Sep 23, 2018

SINGAPORE — European and Asian shares rose on Tuesday, shrugging off U.S. President Donald Trump's decision to place tariffs on an additional $200 billion of Chinese goods starting next week. KEEPING SCORE: In Europe, France's CAC 40 added 0.2 percent to 5,361, while the DAX in Germany rose 0.3 percent to 12,126. Britain's FTSE 100 gained 0.2 percent to 7,316. Wall Street was set to open higher. Dow and S&P 500 futures were both up 0.2 percent. ASIA'S DAY: Japan's Nikkei 225, reopening after a national holiday, jumped 1.4 percent to 23,420.54. The Kospi in South Korea added 0.3 percent...

Penggerak pasaran mengikut TradingView

About Us

Duniaga is Malaysia’s top local source for business news and information where people head to stay connected with the business news. We give daily in-depth analysis on the business happenings in the country.

Contact us: sales[at]duniaga.com

Subscribe Now!